NGM Biopharmaceuticals, Inc. is a privately held drug discovery company dedicated to developing transformational medicines that significantly improve human health. NGM has established a unique, proprietary research and discovery platform based on understanding and leveraging the relationship between bariatric gastric bypass surgery in type 2 diabetic patients and observed post-surgical therapeutic benefits. NGM is generating a rich pipeline of new targets that the Company can use to develop novel treatments for metabolic diseases, such as obesity, muscle wasting and cardiovascular disease in addition to diabetes. Founded in 2008, NGM has an elite executive team with broad experience in building and managing biotechnology companies, and is supported by investors who are committed to the Company's success.

NGM is headquartered in South San Francisco.